You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today.

The Vista+™ Product Advantage

Vista+™ is Eye Co's triamcinolone acetonide formulation. It is uniquely presented in a unit dose syringe providing the treating physician with significant benefits in handling, dosage accuracy and reduced risk of infection as well as cost.

This product line is sold in Australia to approximately 45 eye clinics, day hospitals and public hospitals.

Vista+™ manufacture is protected by trade secrets and copyrighted formulations, and is sold and used today throughout Australia. Surgeons use the product intra-operatively in vitreous and complex cataract surgery, and also to stop inflammation/boost function in patients suffering from uveitis, wet macular degeneration, occlusion of various vessels in the back of the eye, and in diabetic retinal disease.

Eye Co is organized to manufacture and sell, internationally and in Australia, a ‘compounded' product Vista+™, an intravitreal injection for ocular use with the following advantages.



  • Intravitreal triamcinolone acetonide (IVTA) has many broad applications to the eye including Diabetic Retinopathy-associated Cataract, Occult Macular Degeneration and Uveitis.
  • Numerous recent studies recommend its adjunct usage in conjunction with bevacizumab, and with laser (PDT), for Diabetic Retinopathy.
  • Vista+™ has been specially formulated to be preservative free, consistent with current ophthalmic best practise recommendations.
  • Vista+™ is supplied in a pre-filled syringe avoiding sterility risks associated with multi-use vials.

Intellectual Property:

Eye Co has a series of granted global and regional patents and patents at various stages of acceptance.

Eye Co's IP portfolio also extends to a series of trade secrets relating to the manufacture and use of its product portfolio.

Published Clinical Data

Steroids: role in Diabetic Retinopathy
Steroids: role in Macular Oedema
Steroids: role in Age Related Macular Degeneration